Title | Getting a lead on Pb2+-amide chelators for 203/212Pb radiopharmaceuticals |
Publication Type | Journal Article |
Year of Publication | 2021 |
Authors | Ingham, A, Kostelnik, TI, McNeil, BL, Patrick, BO, Choudhary, N, Jaraquemada-Pelaez, Mde Guadalu, Orvig, C |
Journal | Dalton Trans. |
Volume | 50 |
Pagination | 11579-11595 |
Date Published | 08/2021 |
Abstract | Amide-based chelators DTPAm{,} EGTAm and ampam were synthesized to investigate which chelator most ideally coordinates [nat/203Pb]Pb2+ ions for potential radiopharmaceutical applications. 1H NMR spectroscopy was used to study each metal–ligand complex in the solution state. The 1H NMR spectrum of [Pb(DTPAm)]2+ revealed minimal isomerization and fluxional behaviour compared to [Pb(EGTAm)]2+ and [Pb(ampam)]2+{,} both of which showed fewer spectral changes indicative of less static behaviour. The solid-state coordination properties of each complex were also examined from single crystal structures that were studied by X-ray diffraction (XRD). In the solid-state{,} octadentate DTPAm coordinated Pb2+ to form an eight-coordinate hemidirected complex; octadentate EGTAm coordinated Pb2+ forming a ten-coordinate holodirected complex with a bidentate NO3− ion also coordinated to the metal centre; decadentate ampam completely encapsulated the Pb2+ ion to form a ten-coordinate holodirected complex with a C2 axis of symmetry. Potentiometric titrations were carried out to assess the thermodynamic stability of each metal–ligand complex. The pM values obtained for [Pb(DTPAm)]2+{,} [Pb(EGTAm)]2+ and [Pb(ampam)]2+ were 9.7{,} 7.2 and 10.2{,} respectively. The affinity of each chelator for Pb2+ ions was tested by [203Pb]Pb2+ radiolabeling studies to evaluate their prospects as chelators for [203/212Pb]Pb2+-based radiopharmaceuticals. DTPAm radiolabeled [203Pb]Pb2+ ions achieving molar activities as high as 3.5 MBq μmol−1 within 15 minutes{,} at 25 °C{,} whereas EGTAm and ampam produced lower molar activities of 0.25 MBq μmol−1 within 30 minutes{,} at 37 °C. EGTAm and ampam were therefore deemed unsuitable for [203/212Pb]Pb2+-based radiopharmaceutical applications{,} while DTPAm warrants further studies. |
URL | http://dx.doi.org/10.1039/D1DT01653A |
DOI | 10.1039/D1DT01653A |
Refereed Designation | Refereed |